Academic Journal

JAMA Psychiatry

22 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Paywallmeta

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

This systematic review and meta‑analysis of 214 studies (3,504 participants with analysable adverse‑event data) found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings, with serious adverse events occurring mainly in ~4% of participants who had preexisting neuropsychiatric disorders and no reports in contemporary trials of suicide, persistent psychotic disorder or hallucinogen‑persisting perception disorder. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance.

Published
Journal
JAMA Psychiatry
Authors
Graziosi, M., Hinkle, J. T., Nayak, S., Yaden, D. B.
Open Accessindividual

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes

In an open‑label, non‑randomised 12‑week trial of 15 patients with treatment‑resistant bipolar II depression, a single 25 mg dose of synthetic psilocybin plus psychotherapy produced large, rapid and sustained reductions in depressive symptoms (mean MADRS change −24 points at 3 weeks; 12/15 responders, 11/15 remissions) without significant increases in mania or suicidality. These preliminary results suggest psilocybin may be an effective and safe acute treatment for bipolar II depression and merit confirmation in larger randomised controlled trials.

Published
Journal
JAMA Psychiatry
Authors
Aaronson, S. T., LaPratt, J., Lauterbach, M., Miller, T., Sackeim, H. A., Shoultz, A., Suppes, T., Swartz, K., van der Vaart, A.

Quick Facts

Papers Indexed
22
h-Index
417
Open Access
No
Publisher
American Medical Association
Country
United States
Website
Visit